%0 Clinical Trial Protocol
%T Sildenafil Versus Placebo for Early Pulmonary Vascular Disease in Scleroderma (SEPVADIS): protocol for a randomized controlled trial.
%A Lammi MR
%A Mukherjee M
%A Saketkoo LA
%A Carey K
%A Hummers L
%A Hsu S
%A Krishnan A
%A Sandi M
%A Shah AA
%A Zimmerman SL
%A Hassoun PM
%A Mathai SC
%J BMC Pulm Med
%V 24
%N 1
%D 2024 Apr 30
%M 38689245
%F 3.32
%R 10.1186/s12890-024-02892-3
%X <B>BACKGROUND: </B>Pulmonary hypertension (PH) is a leading cause of death in patients with systemic sclerosis (SSc). An important component of SSc patient management is early detection and treatment of PH. Recently the threshold for the diagnosis of PH has been lowered to a mean pulmonary artery pressure (mPAP) threshold of > 20 mmHg on right heart catheterization (RHC). However, it is unknown if PH-specific therapy is beneficial in SSc patients with mildly elevated pressure (SSc-MEP, mPAP 21-24 mmHg).<BR><B>METHODS: </B>The SEPVADIS trial is a randomized, double-blind, placebo-controlled phase 2 trial of sildenafil in SSc-MEP patients with a target enrollment of 30 patients from two academic sites in the United States. The primary outcome is change in six-minute walk distance after 16 weeks of treatment. Secondary endpoints include change in pulmonary arterial compliance by RHC and right ventricular function by cardiac magnetic resonance imaging at 16 weeks. Echocardiography, serum N-terminal probrain natriuretic peptide, and health-related quality of life is being measured at 16 and 52 weeks.<BR><B>CONCLUSIONS: </B>The SEPVADIS trial will be the first randomized study of sildenafil in SSc-MEP patients. The results of this trial will be used to inform a phase 3 study to investigate the efficacy of treating patients with mild elevations in mPAP.<BR><B>BACKGROUND: </B>ClinicalTrials.gov Identifier NCT04797286.